Composition for inducing direct transdifferentiation of somatic cell into vascular progenitor cell, and use thereof

Patent metadata

Field	Value
Publication number	US-10174287-B2
Application number	US-201515120171-A
Country	US
Kind code	B2
Filing date	Mar 3, 2015
Priority date	Mar 3, 2014
Publication date	Jan 8, 2019
Grant date	Jan 8, 2019

Abstract

The present invention relates to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell and a use thereof and, more specifically, to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell, a pharmaceutical composition for the prevention or treatment of ischemic vascular diseases, a cell therapeutic agent for the prevention or treatment of ischemic vascular diseases, a composition for screening a therapeutic drug for ischemic vascular diseases, a 3D printing biological material composition for the production of an artificial tissue for the treatment of ischemic vascular diseases, and a method for direct transdifferentiation of a somatic cell into a vascular progenitor cell. By producing a vascular progenitor cell by direct transdifferentiation of a somatic cell according to the present invention, it is possible to reduce the production period of the vascular progenitor cell and to avoid the formation of teratoma, which is a side effect of an induced pluripotent stem cell, thereby minimizing the side effects of a stem cell therapeutic agent.

First claim

The invention claimed is:

1. A method of inducing a direct transdifferentiation of a somatic cell into a vascular progenitor cell, comprising
introducing one protein selected from the group consisting of ETV2 (ETS variant gene 2), and a combination of FLI1 (Friend leukemia virus integration 1) and ETV2,
a nucleic acid molecule encoding the protein selected from the group consisting of ETV2, and a combination of FLI1 and ETV2, or
a vector comprising the nucleic acid molecule, to a somatic cell, and
wherein a vascular progenitor cell is formed directly from the somatic cell,
wherein the somatic cell is a cell selected from the group consisting of a fibroblast, a muscle cell, a nerve cells, a gastric mucosal cell, a goblet cells, a G cells, a pericyte, an astrocyte, a B cell, a blood cell, an epithelial cell, a neural stem cell, a hematopoietic stem cell, a cord blood stem cell, and a mesenchymal stem cell.

2. The method of claim 1 , wherein the vector is at least one selected from the group consisting of a plasmid vector, a cosmid vector, a viral vector, and an episomal vector.

3. The method of claim 2 , wherein the viral vector is at least one selected from the group consisting of a retrovirus vector, an adenovirus vector, an adeno-associated virus, and a Herpes simplex virus vector.

4. The method of claim 3 , wherein the retrovirus vector is at least one selected from the group consisting of a lentivirus vector, a HIV (Human Immunodeficiency Virus) vector, a MLV (Murine Leukemia Virus) vector, an ASLV (Avian Sarcoma/Leukosis) vector, a SNV (Spleen Necrosis Virus) vector, a RSV (Rous Sarcoma Virus) vector, and a MMTV (Mouse Mammary Tumor Virus) vector.

Assignees

• Ulsan Nat Inst Science & Tech Unist

Inventors

• Kim Jeong Beom

Classifications

• C12N2506/1307

  from adult fibroblasts · CPC title

• C12N2501/998

  Proteins not provided for elsewhere · CPC title

• C12N15/86

  Viral vectors · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• G01N33/5008

  for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics · CPC title